Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
EP395 is an orally available macrolide or ‘Barriolide™‘ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease).
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases.
Lead Product(s): UPB-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: UPB-101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2022
Details:
These studies have generated positive results showing RP-323 (12-O-tetradecanoylphorbol-13-acetate) significantly reduces the influx of inflammatory cells into the lungs thereby limiting damage to the lungs.
Lead Product(s): 12-O-Tetradecanoylphorbol-13-acetate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RP-323
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
DWN12088 is world's first PRS inhibitory anti-fibrotic agent,demonstrated excellent anti-fibrotic and pulmonary function improvement effects by co-administering DWN12088 and existing drugs in an animal model.
Lead Product(s): DWN12088
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DWN12088
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
Positive effects for Trans Sodium Crocetinate on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval.
Lead Product(s): Trans Crocetinate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
C106 is first of four advanced candidate drugs from VP03 program to enter clinical trials. C106 and the three additional candidates are small molecules with high affinity for AT2R and intended for indications also outside rare lung disease.
Lead Product(s): CAS 138564-60-0
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C106
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program ISM001-55 (INS018_055) which is currently in a Phase I study, and continued development of its Pharma.AI platform.
Lead Product(s): ISM001-55
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS018_055
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: BHR Partners
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 06, 2022
Details:
EP395, is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’, to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD).
Lead Product(s): EP395
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
KER-012 is designed to bind to and inhibit signaling of TGF-ß ligands that suppress bone growth, including activin A and activin B, being developed for treatment of Pulmonary arterial hypertension and for treatment of disorders associated with bone loss.
Lead Product(s): KER-012
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KER-012
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).
Lead Product(s): Cudetaxestat,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLD-0409
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
